BUSINESS UPDATE: Celadon Pharmaceuticals Plc (CEL) Announces submission of its Chronic Pain feasibility study

Celadon Pharmaceuticals Plc is pleased to report that LVL Health, our private pain clinic subsidiary, has completed the feasibility study for its non-cancer chronic pain clinical trial, and submitted the results to the Research Ethics Committee for approval.
The larger clinical trial, which has already received conditional approval from the MHRA, is designed to provide a data set that will enable the potential for prescription and reimbursement on the UK’s NHS, as well as giving doctors more data to prescribe.
Read More: https://www.londonstockexchange.com/news-article/CEL/results-of-feasibility-study/15776764
OTHER POSTS
-
PRESS: Britain could be getting high on the benefits of a full-scale medical cannabis industry
-
PRESS: British Pain Society features Celadon Pharmaceuticals Plc
-
PRESS: Celadon Pharmaceutical’s CEO Jim Short featured discussing new MHRA framework
-
PRESS: Inside huge top-secret legal cannabis facility hidden away in Birmingham that is the size of three football pitches